In Silico Protein-Ligand Docking Studies on Thiazolidinediones as Potential Anticancer Agents

Molecular docking study was performed on a series of 24 Thiazolidinediones MM1-MM24 as potential epiderma1 growth factor receptor (EGFRR) inhibitors. The docking technique was applied to dock a set of representative compounds within the active site region of 1M17 using Molegro Virtual Docker v 5.0. For these compounds, the binding free energy (kcal/mol) was determined. The docking simulation clearly predicted the binding mode that is nearly similar to the crystallographic binding mode with 1.34A RMSD. Based on the validations and hydrogen bond interactions made by R substituents were considered for evaluation. The results avail to understand the type of interactions that occur between thiazolidinediones with 1M17 binding site region and explain the importance of R substitution on thiazolidinedione basic nucleus.

[1]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[2]  Mechanism of action of adverse drug reactions: an overview. , 1997, Pharmacoepidemiology and drug safety.

[3]  R. Storn,et al.  Differential Evolution - A simple and efficient adaptive scheme for global optimization over continuous spaces , 2004 .

[4]  L. Bohlin,et al.  Flavan-3-ols Isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis , 1998, Planta medica.

[5]  David B. Fogel,et al.  Docking Conformationally Flexible Small Molecules into a Protein Binding Site through Evolutionary Programming , 1995, Evolutionary Programming.

[6]  L Lasagna,et al.  New drug development in the United States from 1963 to 1990 , 1991, Clinical pharmacology and therapeutics.

[7]  Larry L. Peterson,et al.  Reasoning about naming systems , 1993, TOPL.

[8]  C Y Ung,et al.  Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants. , 2002, The American journal of Chinese medicine.

[9]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules J. Am. Chem. Soc. 1995, 117, 5179−5197 , 1996 .

[10]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[11]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[12]  R Nussinov,et al.  Flexible docking allowing induced fit in proteins: Insights from an open to closed conformational isomers , 1998, Proteins.

[13]  V. Avupati,et al.  De novo Based Ligand generation and Docking studies of PPARδ Agonists: Correlations between Predicted Biological activity vs. Biopharmaceutical Descriptors , 2010 .

[14]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[15]  T. Schmidt,et al.  Autoregulation of corticosteroid receptors. How, when, where, and why? , 1994, Receptor.

[16]  Rainer Storn,et al.  Differential Evolution – A Simple and Efficient Heuristic for global Optimization over Continuous Spaces , 1997, J. Glob. Optim..

[17]  L Lasagna,et al.  New drug development in the United States from 1963 to 1992 , 1994, Clinical pharmacology and therapeutics.

[18]  I. Kuntz,et al.  Flexible ligand docking: A multistep strategy approach , 1999, Proteins.

[19]  Schmidt Tj,et al.  Autoregulation of corticosteroid receptors. How, when, where, and why? , 1994 .

[20]  L. Gianaroli,et al.  Molecular and cellular endocrinology , 1992, Molecular and Cellular Endocrinology.

[21]  J. D. Elliott,et al.  Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.

[22]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[23]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.